Free Trial
NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

MoonLake Immunotherapeutics logo
$54.88 -0.77 (-1.38%)
Closing price 04:00 PM Eastern
Extended Trading
$54.78 -0.10 (-0.18%)
As of 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

Key Stats

Today's Range
$54.00
$56.00
50-Day Range
$42.90
$55.74
52-Week Range
$31.42
$58.26
Volume
269,260 shs
Average Volume
479,210 shs
Market Capitalization
$3.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.43
Consensus Rating
Moderate Buy

Company Overview

MoonLake Immunotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

MLTX MarketRank™: 

MoonLake Immunotherapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 640th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MoonLake Immunotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MoonLake Immunotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about MoonLake Immunotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.79) to ($2.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MoonLake Immunotherapeutics is -19.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MoonLake Immunotherapeutics is -19.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MoonLake Immunotherapeutics has a P/B Ratio of 9.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.00% of the float of MoonLake Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MoonLake Immunotherapeutics has recently decreased by 3.31%, indicating that investor sentiment is improving.
  • Dividend Yield

    MoonLake Immunotherapeutics does not currently pay a dividend.

  • Dividend Growth

    MoonLake Immunotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.00% of the float of MoonLake Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MoonLake Immunotherapeutics has recently decreased by 3.31%, indicating that investor sentiment is improving.
  • News Sentiment

    MoonLake Immunotherapeutics has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for MoonLake Immunotherapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for MLTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    11 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MoonLake Immunotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.02% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MoonLake Immunotherapeutics' insider trading history.
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLTX Stock News Headlines

MoonLake Immunotherapeutics: Maintaining A Small Holding
Wedbush Issues Pessimistic Estimate for MLTX Earnings
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Headlines

MLTX Stock Analysis - Frequently Asked Questions

MoonLake Immunotherapeutics' stock was trading at $54.15 at the beginning of the year. Since then, MLTX stock has increased by 1.3% and is now trading at $54.88.

MoonLake Immunotherapeutics (NASDAQ:MLTX) issued its earnings results on Tuesday, August, 5th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by $0.14.

Top institutional investors of MoonLake Immunotherapeutics include Westfield Capital Management Co. LP (1.97%), Federated Hermes Inc. (1.95%), Alliancebernstein L.P. (1.78%) and Hood River Capital Management LLC (1.06%). Insiders that own company stock include Bihua Chen, Da Silva Jorge Santos, Matthias Bodenstedt, Simon Sturge and Kristian Reich.
View institutional ownership trends
.

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MoonLake Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Disc Medicine (IRON), e.l.f. Beauty (ELF), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/05/2025
Today
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MLTX
CIK
1821586
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

High Price Target
$100.00
Low Price Target
$61.00
Potential Upside/Downside
+33.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$118.94 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-40.98%
Return on Assets
-35.81%

Debt

Debt-to-Equity Ratio
0.21
Current Ratio
16.65
Quick Ratio
16.65

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.59 per share
Price / Book
9.97

Miscellaneous

Outstanding Shares
64,012,000
Free Float
56,318,000
Market Cap
$3.57 billion
Optionable
Optionable
Beta
1.27
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:MLTX) was last updated on 8/14/2025 by MarketBeat.com Staff
From Our Partners